Renaissance Capital logo

NEOS News

US IPO Weekly Recap: All natural pet food maker is top dog in a week with three IPOs

BUFF

Every dog has its day, and this week it was Blue Buffalo: the year's fifth-largest IPO surged over 30%. All three initial public offerings this week raised more capital than expected as Blue Buffalo priced above its range while Neos and Live Oak offered additional shares. Each had double-digit returns....read more

Neos Therapeutics prices upsized IPO at the $15 midpoint

NEOS

Neos Therapeutics, which is developing easily swallowed formulations of ADHD treatments, raised $72 million by offering 4.8 million shares (upsized from 4.0 million) at $15, the midpoint of the range of $14 to $16. Neos Therapeutics plans to list on the Nasdaq under the symbol NEOS. Neos Therapeutics initially filed confidentially on 4/27/2015. UBS Investment Bank, BMO Capital...read more

Week ahead: 5 IPOs during the week of July 20 are led by a Blue Buffalo

BUFF

Fast-growing and highly-profitable pet food maker Blue Buffalo could be top dog this week. Five businesses and one blank check company are on the IPO calendar to raise over $1 billion. The third quarter has already seen more consumer IPOs than the first quarter, and Blue Buffalo will be the third. Yet...read more

ADHD biotech Neos Therapeutics sets terms for $60 million IPO

NEOS

Neos Therapeutics, a late stage biotech developing extended release formulations of ADHD therapies, announced terms for its IPO on Monday. The Grand Prairie, TX-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, it would command a fully diluted market value of $220 million. Neos...read more